|
Market Cap (25-Jun) $7,649,007 (1,598th) |
Close (30-Jun) $0.024 |
Volume (30-Jun) 2,170,184 |
Shortsold (2-Feb) 3,141 (0.00%) (662nd) |
|
52w High $0.008 |
52w Low $0.002 |
P/E - |
EPS 0 |
1AD released this announcement to the ASX on 9 November 2020, 8:21. The announcement is not marked as price sensitive, and is 2 page(s) in length and 290.69kb in size.
You can view all announcements from 1AD and see how they appear on a price chart on the announcements page.
At the date of this announcement, 1AD was 0.000% short sold according to ASIC data. It was ranked the 583rd most shorted stock on the ASX. It remains ranked 662nd as of the latest reported data (02 February 2021).
| Other Recent Announcements from 1AD | |
|---|---|
| AD-214 clinical trial approval | 29 June 2023, 8:21 |
| Change in substantial holding | 31 May 2023, 13:30 |
| Change in substantial holding | 31 May 2023, 9:34 |
| Notification of Expired Options | 9 November 2020, 8:21 |
| AusBiotech presentation including Phase I status update | 27 October 2020, 8:27 |
| Notice of Annual General Meeting/Proxy Form | 22 October 2020, 8:19 |
| Annual General Meeting - Letter to Shareholders | 22 October 2020, 8:18 |
You must be logged in to post a reply.
AdAlta 